Patient Preferences in Neuromuscular Diseases: Insights for Future Drug Development
JIMD Reports · 2026-07 · 67 (4)
DOI: 10.1002/jmd2.70100 ↗Kurz gefasst
Fachartikel in der Zeitschrift JIMD Reports, online erschienen am 01.06.2026. Verfasst von Aura Cecilia Jimenez-Moreno und 10 weiteren Autor:innen. Beteiligte Einrichtung: Wellcome Centre for Mitochondrial Research. Translational and Clinical Research Institute. Faculty of Medical Sciences, Newcastle University Newcastl…. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.
Abstract (Originalsprache)
Incorporating patient preferences into drug development is crucial, particularly, for rare diseases with significant unmet needs. This study used Best‐Worst Scaling type 2 (BWS‐2) to explore benefit–risk trade‐offs for patients and caregivers in two rare neuromuscular diseases (NMDs), myotonic dystrophy type 1 (DM1), and mitochondrial myopathy (MM). Patients with DM1 and MM, along with caregivers, completed a BWS‐2 survey assessing four treatment benefits (muscle strength, energy and endurance, balance, cognition) and two risks (permanent liver damage, temporary blurring of vision). Participants were stratified by disease group and age of onset (< 20, ≥ 20 years). A latent class analysis was used to calculate the relative importance of each treatment attribute. Sociodemographic and disease‐related data were also collected. A total of 270 participants (DM1 n = 143, MM n = 127, including 37 caregivers) were included. BWS‐2 results revealed a priority for improvements in muscle strength (24%), and energy and endurance (23%) across all groups, with caregivers placing a higher priority on cognition improvements (17%) compared to patients. There were no significant differences between disease groups or by age of onset. This study underscores the importance of patient preferences in drug development for rare NMDs. The consensus on treatment priorities across both diseases suggests that overlapping clinical features can inform and expedite future NMD or rare disease drug development.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Wellcome Centre for Mitochondrial Research. Translational and Clinical Research Institute. Faculty of Medical Sciences, Newcastle University Newcastle upon Tyne UK.
- National Institute for Health and Care Research (NIHR) Newcastle Biomedical Research Centre (BRC) Newcastle upon Tyne UK.
- Newcastle upon Tyne Hospitals NHS Foundation Trust Newcastle upon Tyne UK.
- NHS Highly Specialised Service for Rare Mitochondrial Disorders of Adults and Children, Newcastle Upon Tyne Hospitals NHS Foundation Trust Newcastle upon Tyne UK.
- Kielo Research York UK.
- Merck & Co., Inc. Rahway New Jersey USA.
ORCID-Profile: Aura Cecilia Jimenez-Moreno
Förderung
- Wellcome Trust
Zitieren
APA
Jimenez-Moreno, A. C., Blain, A., Pinto, C. A., Soekhai, V., Johansson, J. V., Dyer, C., Adcock, K., de Bekker-Grob, E. W., de Wit, G. A., Newman, J., & Gorman, G. S. (2026). Patient Preferences in Neuromuscular Diseases: Insights for Future Drug Development. JIMD Reports, 67(4). https://doi.org/10.1002/jmd2.70100
Vancouver
Jimenez-Moreno AC, Blain A, Pinto CA, Soekhai V, Johansson JV, Dyer C, et al. Patient Preferences in Neuromuscular Diseases: Insights for Future Drug Development. JIMD Reports. 2026;67(4). doi:10.1002/jmd2.70100
BibTeX
@article{JimenezMoreno2026,
author = {Jimenez-Moreno, Aura Cecilia and Blain, Alasdair and Pinto, Cathy Anne and Soekhai, Vikas and Johansson, Jennifer Viberg and Dyer, Christine and Adcock, Kate and de Bekker-Grob, Esther W and de Wit, G Ardine and Newman, Jane and Gorman, Gráinne S},
title = {Patient Preferences in Neuromuscular Diseases: Insights for Future Drug Development},
journal = {JIMD Reports},
year = {2026},
volume = {67},
number = {4},
doi = {10.1002/jmd2.70100}
}
EUVIMED